AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study

Recruitingn/aAges 18 Years - anyAllI.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Peripheral arterial disease involving the iliac arteries is a common manifestation of systemic atherosclerosis and a major cause of lifestyle-limiting claudication and chronic limb-threatening ischemia. Endovascular iliac artery stenting has become the preferred treatment strategy for most iliac lesions, including complex TransAtlantic Inter-Society Consensus II (TASC II) C and D lesions, owing to high technical success rates and lower perioperative morbidity compared with open surgical reconstruction. Despite widespread adoption of endovascular treatment, available evidence regarding predictors of major adverse limb events (MALE) after iliac artery stenting remains limited, particularly in unselected real-world populations with substantial comorbidity burden. Patient-related factors, including frailty, may contribute to post-procedural outcomes in addition to lesion-related characteris

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Adult patients aged โ‰ฅ18 years, of both male and female sex * Presence of haemodynamically significant stenosis or occlusion of the common iliac artery (CIA) and/or external iliac artery (EIA), documented by computed tomography angiography, magnetic resonance angiography, or diagnostic angiography * Symptomatic peripheral artery disease, including lifestyle-limiting intermittent claudication (Rutherford category 2-3) or chronic limb- threatening ischaemia (CLTI; Rutherford category 4-6), refractory to optimal medical therapy * Treatment with endovascular iliac artery stenting (covered or uncovered; balloon-expandable or self-expanding devices) as the primary revascularisation strategy * De novo iliac lesions only * Availability of complet Exclusion Criteria: Primary open surgical revascularisation of the iliac axis (e.g., aorto- bifemoral bypass or endarterectomy). * Previous stenting of the target iliac segment (in-stent restenosis cases excluded). * Aorto-iliac aneurysmal disease as the primary indication for treatment (including EVAR or fenestrated endografts). * Hybrid procedures with concomitant infrainguinal bypass surgery. * Incomplete clinical, procedural, or follow-up data preventing assessment of study endpoints. * Loss to follow-up without documented clinical outcomes.
๐Ÿ’Š

What it tests

  • Iliac stenting
๐Ÿ“

Where

1 site
IRCCS Galeazzi Sant'Ambrogio Hospital
Milan, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy